12 results
By means of resting state network measurments using fMRI we hope to gain more knowlegde about the actions (for example as an analgesic) an side effects of S(+)-ketamine on the central nervous system at different doses. Also blood samples will be…
1. To quantify the influence of propofol on the distribution, redistribution and elimination of ketamine and to evaluate the importance of hemodynamic parameters on the pharmacokinetics of ketamine.2. To quantify the influence of ketamine on the…
To study the effect of acetazolamide on lithium-induced NDI.
The objectives are to assess the pharmacokinetic and pharmacodynamic effects of sub-anesthetic ketamine administration, to assess the optimal dose of ketamine and gender differences, to compare different oucome measures for psychomimetic symptoms…
In a fMRI experiment, will measure the changes in brain activity patterns and in functional connectivity. We hypothesize that a subanesthetic dose of S-Ketamine impairs the functional connectivity, especially the feedback connections that are…
Primary aim:The primary aim of this study is to evaluate the effect of two consecutive infusions of S(+)-ketamine in patients with CRPS-I on pain relief. The design of the study is prospective, randomised, double-blind and placebo-controlled.…
1. Measure DNIC and offset analgesia in CRPS-1 patients, fibromyalgia patients and neuropathic pain patients;2. Compare DNIC and offset analgesia in chronic pain patients with DNIC and offset analgesia in healthy volunteers;3. Assess the effect of…
To investigate the effectiveness of s-ketamine as add-on medication to a multimodal pain approach with acetaminophen and opioids compared to placebo with the same multimodal pain approach on the total postoperative opioid consumption, the…
The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days. The end of study is at 6…
The aim of the current study is to extend the time to develop new disease progression in prostate cancer patients with recurrent disease in the form of limited metastases (<5) and in some cases possibly even cure by adding 6 months of ADT to…
Primary:• To evaluate the ability of relugolix to achieve and maintain serum testosterone suppression to castrate levels (<= 50 ng/dL [1.7 nmol/L]) in men with androgen-sensitive advanced prostate cancer.Secondary:• To evaluate the time…
All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.